Incidence Patterns and Trends of non-Central Nervous System Solid Tumours in Children and Adolescents. A Collaborative Study of the Spanish Population Based Cancer Registries.
Larrañaga N, Sanchez MJ, Ardanaz E, Felipe S, Marcos-Gragera R, Ramos M, Carulla M, Chirlaque MD, Argüelles MV, Martos C, Mateo A, Peris-Bonet R.
Journal Of Cancer. 2016; 7: 335-343. FI: 2,916 (Q3).
Prevalence of altered mismatch repair protein nuclear expression detected by immunohistochemistry on adenomas with high-grade dysplasia and features associated with this risk in a population-based study.
Basterra M, Gomez M, Mercado Mdel R, Irisarri R, Amorena E, Arrospide A, Montes M, Aisa G, Cambra KI, Urman J.
Gastroenterologia Y Hepatologia. 2016; 39: 500-507. FI: 0,917 (Q4).
Advanced prostate cancer survival in Spain according to the Gleason score, age and stage.
Campá J, Mar-Barrutia G, Extramiana J, Arróspide A, Mar J.
Actas Urologicas Espanolas. 2016; 40: 499-506. FI: 1,181 (Q4).
Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain.
Castilla-Rodriguez I, Cela E, Vallejo-Torres L, Valcarcel-Nazco C, Dulin E, Espada M, Rausell D, Mar J, Serrano-Aguilar P.
Expert Opinion On Orphan Drugs. 2016; 4: 567-575. FI: 0,559 (Q4).
A polyarticular onset and diabetes could be the main predictors of cardiovascular events in psoriatic arthritis.
Tejón P, Morante I, Cabezas I, Sarasqueta C, Coto P, Queiro R.
Clinical And Experimental Rheumatology. 2016; 34: 276-281. FI: 2,634 (Q3).
Cellular immune activity biomarker neopterin is associated hyperlipidemia: results from a large population-based study.
Chuang SC, Boeing H, Vollset SE, Midttun Ø, Ueland PM, Bueno-de-Mesquita B, Lajous M, Fagherazzi G, Boutron-Ruault MC, Kaaks R, Küehn T, Pischon T, Drogan D, Tjønneland A, Overvad K, Quirós JR, Agudo A, Molina-Montes E, Dorronsoro M, Huerta JM, Barricarte A, Khaw KT, Wareham NJ, Travis RC, Trichopoulou A, Lagiou P, Trichopoulos D, Masala G, Agnoli C, Tumino R, Mattiello A, Peeters PH, Weiderpass E, Palmqvist R, Ljuslinder I, Gunter M, Lu Y, Cross AJ, Riboli E, Vineis P, Aleksandrova K.
Immunity & Ageing. 2016; 13: 5-5. FI: 2,216 (Q3).
Análisis coste-efectividad del tratamiento de la hepatitis C crónica con sofosbuvir-simeprevir en pacientes con genotipo 1 y fibrosis avanzada.
Mar J, Mar-Barrutia L, Gimeno-Ballester V, San Miguel R.
Medicina Clinica. 2016; 146: 61-64. FI: 1,125 (Q3).
Validation and comparison of instruments to identify frail patientes in primary care settings: Study protocol.
Vergara I, Rivas-Ruiz F, Vrotsou K, Contreras-Fernández E, Téllez-Santana T, Machón M, Díez Ruiz AI, de Mesa Berenguer Y, Bueno A, Núñez J, Saucedo Figueredo MC, Montiel-Luque A, Nava Del Val MA, Quirós-López R, Carrasco E, Abellan G.
Bmc Health Services Research. 2016; 16: 354-354. FI: 1,827 (Q3).
Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model.
Hoffmeister L, Lavados PM, Mar J, Comas M, Arrospide A, Castells X.
Journal Of The Neurological Sciences. 2016; 365: 59-64. FI: 2,295 (Q3).
Use of hierarchical models to analyze European trends in congenital anomaly prevalence.
Cavadino A, Prieto-Merino D, Addor MC, Arriola L, Bianchi F, Draper E, Garne E, Greenlees R, Haeusler M, Khoshnood B, Kurinczuk J, McDonnell B, Nelen V, O'Mahony M, Randrianaivo H, Rankin J, Rissmann A, Tucker D, Verellen-Dumoulin C, de Walle H, Wellesley D, Morris JK
Birth Defects Research Part A-Clinical And Molecular Teratology. 2016; 106: 480-488. FI: 1,762 (Q3).
Proposal to inform European institutions regarding the regulation of conscientious objection to abortion.
Lertxundi R, Ibarrondo O, Merki-Feld GS, Rey-Novoa M, Rowlands S, Mar J.
European Journal Of Contraception And Reproductive Health Care. 2016; 21: 198-200. FI: 1,627 (Q3).
Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): An Ecological Study in the Basque Country, Spain (2000-2011).
Tamayo-Uria I, Altzibar JM, Mughini-Gras L, Dorronsoro M.
Copd-Journal Of Chronic Obstructive Pulmonary Disease. 2016; 13: 726-733. FI: 2,576 (Q3).
Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.
Gimeno-Ballester, Vicente, Simón, Miguel Ángel, Trigo, Cristina, MAR MEDINA, JAVIER, San Miguel, Ramón
Expert Rev Gastroent. 2016; 10: 1289-1303. FI: 2,743 (Q3).
Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial.
Lanzeta I, Mar J, Arrospide A.
Gaceta Sanitaria. 2016; 30: 352-358. FI: 1,768 (Q3).
